NASDAQ:OCX OncoCyte (OCX) Stock Price, News & Analysis → The Overlooked Retirement Asset You Probably Don’t Own (From Crypto 101 Media) (Ad) Free OCX Stock Alerts $2.93 -0.14 (-4.56%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$2.91▼$3.0850-Day Range$2.44▼$3.0752-Week Range$2.08▼$5.40Volume32,031 shsAverage Volume31,399 shsMarket Capitalization$24.23 millionP/E RatioN/ADividend YieldN/APrice Target$4.06 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get OncoCyte alerts: Email Address OncoCyte MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside38.7% Upside$4.06 Price TargetShort InterestBearish3.64% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.03Based on 10 Articles This WeekInsider TradingAcquiring Shares$7.18 M Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.39 out of 5 starsMedical Sector705th out of 920 stocksDiagnostic Substances Industry11th out of 13 stocks 3.3 Analyst's Opinion Consensus RatingOncoCyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageOncoCyte has only been the subject of 3 research reports in the past 90 days.Read more about OncoCyte's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.64% of the float of OncoCyte has been sold short.Short Interest Ratio / Days to CoverOncoCyte has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in OncoCyte has recently increased by 60.53%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldOncoCyte does not currently pay a dividend.Dividend GrowthOncoCyte does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OCX. Previous Next 1.7 News and Social Media Coverage News SentimentOncoCyte has a news sentiment score of -0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for OncoCyte this week, compared to 1 article on an average week.Search Interest8 people have searched for OCX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added OncoCyte to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, OncoCyte insiders have bought more of their company's stock than they have sold. Specifically, they have bought $7,176,400.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 1.94% of the stock of OncoCyte is held by insiders.Percentage Held by Institutions55.35% of the stock of OncoCyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about OncoCyte's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioOncoCyte has a P/B Ratio of 2.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about OncoCyte's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market Insidersget a piece of the profit from this land This isn’t the prettiest land on earth. But it might be the most valuable. And you don’t have to own, lease, or rent any land.Click here to see my #1 investment for 2024. About OncoCyte Stock (NASDAQ:OCX)OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.Read More OCX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OCX Stock News HeadlinesMay 7, 2024 | insidertrades.com3 Penny Stocks That Insiders Are Buying (OCX)May 16 at 7:14 PM | markets.businessinsider.comOncoCyte’s Strategic Initiatives and Financial Health Garner Buy RatingMay 16 at 10:35 AM | finanznachrichten.deOncoCyte Corporation: Oncocyte Reports First Quarter 2024 Financial ResultsMay 16 at 8:55 AM | finance.yahoo.comOncoCyte Corp (OCX) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges and ...May 16 at 8:55 AM | markets.businessinsider.com4 Analysts Assess OncoCyte: What You Need To KnowMay 16 at 8:55 AM | msn.comOncoCyte Corporation (NASDAQ:OCX) Q1 2024 Earnings Call TranscriptMay 15, 2024 | globenewswire.comOncocyte Reports First Quarter 2024 Financial ResultsMay 14, 2024 | msn.comOncoCyte Q1 2024 Earnings PreviewMay 13, 2024 | finance.yahoo.comOncocyte to Announce First Quarter 2024 Financial ResultsMay 12, 2024 | americanbankingnews.comOncoCyte (NASDAQ:OCX) Now Covered by StockNews.comMay 7, 2024 | finance.yahoo.comPRISM MarketView Spotlights Oncocyte Corporation as it Works to Disrupt the Precision Diagnostics MarketplaceApril 24, 2024 | markets.businessinsider.comStrong Future Outlook for OncoCyte: Buy Rating and Increased Price Target Amid Positive Partnerships and Financial EfficiencyApril 22, 2024 | msn.comBuffett Grabs More of This Stock, Plus Other Notable Insider BuyingApril 13, 2024 | seekingalpha.comOncoCyte Corporation (OCX) Q4 2023 Earnings Call TranscriptApril 13, 2024 | finance.yahoo.comQ4 2023 OncoCyte Corp Earnings CallApril 12, 2024 | investorplace.comOCX Stock Earnings: OncoCyte Misses EPS, Misses Revenue for Q4 2023April 12, 2024 | msn.comTop 3 Health Care Stocks That May Collapse In Q2April 12, 2024 | finanznachrichten.deOncoCyte Corporation: Oncocyte and Bio-Rad Partner on Global Launch of Transplant AssayApril 12, 2024 | msn.comS&P Futures Tick Lower as Investors Digest Big Bank EarningsApril 12, 2024 | msn.comS&P Futures Tick Lower as Investors Cautiously Await U.S. Big Bank EarningsApril 12, 2024 | msn.comOncocyte announces $15.8 mln private placement of securitiesApril 12, 2024 | globenewswire.comOncocyte Reports Full Year 2023 Financial ResultsApril 11, 2024 | globenewswire.comOncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq RulesApril 11, 2024 | globenewswire.comOncocyte and Bio-Rad Partner on Global Launch of Transplant AssayApril 11, 2024 | markets.businessinsider.comHere's what Wall Street expects from Oncocyte's earningsSee More Headlines Receive OCX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today5/19/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryN/A Current SymbolNASDAQ:OCX CUSIPN/A CIK1642380 Weboncocyte.com Phone(949) 409-7600Fax510-521-3389Employees43Year FoundedN/APrice Target and Rating Average Stock Price Target$4.06 High Stock Price Target$5.00 Low Stock Price Target$3.00 Potential Upside/Downside+38.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,780,000.00 Net Margins-2,905.14% Pretax Margin-2,890.23% Return on Equity-135.45% Return on Assets-48.68% Debt Debt-to-Equity RatioN/A Current Ratio0.78 Quick Ratio1.49 Sales & Book Value Annual Sales$1.50 million Price / Sales16.15 Cash FlowN/A Price / Cash FlowN/A Book Value$1.40 per share Price / Book2.09Miscellaneous Outstanding Shares8,270,000Free Float8,113,000Market Cap$24.23 million OptionableNo Data Beta0.80 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Joshua Riggs (Age 41)President, CEO & Director Comp: $504.63kMr. James Liu (Age 28)Senior Director, Controller, Principal Accounting Officer & Interim Principal Financial Officer Comp: $259.83kDr. Ekkehard Schutz M.D.Ph.D., Chief Science OfficerMr. Peter HongVP, General Counsel & SecretaryMr. Yuh-Min Chiang Ph.D.Senior Vice President of R&D and Product DevelopmentMs. Sandra O'DonaldSenior Vice President of Business OperationsDr. Michael D. West Ph.D. (Age 71)Scientific Advisor, Co-CEO of Biotime,Inc. & President of Biotime,Inc. More ExecutivesKey CompetitorsDURECTNASDAQ:DRRXCardio DiagnosticsNASDAQ:CDIOAspira Women's HealthNASDAQ:AWHTrinity BiotechNASDAQ:TRIBAchilles TherapeuticsNASDAQ:ACHLView All CompetitorsInsidersBroadwood Partners, L.P.Bought 2,420,000 shares on 4/11/2024Total: $7.07 M ($2.92/share)Andrew ArnoBought 33,898 shares on 4/11/2024Total: $99,999.10 ($2.95/share)Josh RiggsBought 3,390 shares on 4/11/2024Total: $10,000.50 ($2.95/share)Alfred D KingsleyBought 1,500 shares on 6/14/2023Total: $6,300.00 ($4.20/share)View All Insider Transactions OCX Stock Analysis - Frequently Asked Questions Should I buy or sell OncoCyte stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" OCX shares. View OCX analyst ratings or view top-rated stocks. What is OncoCyte's stock price target for 2024? 4 brokers have issued 12 month price targets for OncoCyte's shares. Their OCX share price targets range from $3.00 to $5.00. On average, they anticipate the company's share price to reach $4.06 in the next twelve months. This suggests a possible upside of 38.7% from the stock's current price. View analysts price targets for OCX or view top-rated stocks among Wall Street analysts. How have OCX shares performed in 2024? OncoCyte's stock was trading at $2.50 at the beginning of the year. Since then, OCX shares have increased by 17.2% and is now trading at $2.93. View the best growth stocks for 2024 here. When is OncoCyte's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our OCX earnings forecast. How were OncoCyte's earnings last quarter? OncoCyte Co. (NASDAQ:OCX) posted its earnings results on Tuesday, November, 9th. The company reported ($3.00) EPS for the quarter, missing analysts' consensus estimates of ($2.40) by $0.60. The company earned $0.98 million during the quarter, compared to analysts' expectations of $3.20 million. OncoCyte had a negative trailing twelve-month return on equity of 135.45% and a negative net margin of 2,905.14%. When did OncoCyte's stock split? Shares of OncoCyte reverse split on the morning of Tuesday, July 25th 2023. The 1-20 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of OncoCyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other OncoCyte investors own include VBI Vaccines (VBIV), Biocept (BIOC), CymaBay Therapeutics (CBAY), Fulcrum Therapeutics (FULC), Xeris Biopharma (XERS), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), Acasti Pharma (ACST) and Aileron Therapeutics (ALRN). How do I buy shares of OncoCyte? Shares of OCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OCX) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingShocking $16T Elon Musk Crypto LeakCrypto 101 MediaForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsDems have chosen Biden replacement?Paradigm PressHow Biden has already won 2024Porter & CompanyExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersA letter is coming from the "Bureau of the Fiscal Service".Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OncoCyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.